Page last updated: 2024-12-05
n-acetylanthranilic acid
Description
N-acetylanthranilic acid: degradation product or quinaldine; RN given refers to parent cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
N-acetylanthranilic acid : An amidobenzoic acid consisting of anthranilic acid carrying an N-acetyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 6971 |
| CHEBI ID | 36555 |
| SCHEMBL ID | 110042 |
| MeSH ID | M0185850 |
Synonyms (42)
| Synonym |
|---|
| o-acetoaminobenzoic acid |
| CHEBI:36555 |
| o-acetamidobenzoic acid |
| nsc 17831 |
| nsc4000 |
| 2-(acetylamino)benzoic acid |
| anthranilic acid, n-acetyl- |
| acetylanthranilic acid |
| nsc-4000 |
| n-(acetylamino)benzoic acid |
| 2-acetamidobenzoic acid |
| benzoic acid, 2-(acetylamino)- |
| 2-carboxyacetanilide |
| o-acetoaminobenozic acid |
| inchi=1/c9h9no3/c1-6(11)10-8-5-3-2-4-7(8)9(12)13/h2-5h,1h3,(h,10,11)(h,12,13 |
| nsc-17831 |
| nsc17831 |
| OPREA1_069366 |
| 89-52-1 |
| 2-(acetylamino)-benzoic acid |
| n-acetylanthranilic acid |
| C06332 |
| n-acetylanthranilic acid, 99% |
| MAYBRIDGE1_000763 |
| AKOS000280893 |
| HMS543K15 |
| zz8 , |
| unii-p1ie9j75c2 |
| p1ie9j75c2 , |
| A0078 |
| BBL009698 |
| STL141050 |
| FT-0610932 |
| 2-acetamidobenzoicacid |
| SCHEMBL110042 |
| 2-acetylamino benzoic acid |
| n-acetyl anthranilic acid |
| DTXSID9058991 |
| o-acetylaminobenzoic acid |
| o-acetamido benzoic acid |
| dea no. 8522 |
| Q6951344 |
Drug Classes (1)
| Class | Description |
|---|
| amidobenzoic acid | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 42.53
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 42.53 (24.57) | | Research Supply Index | 1.79 (2.92) | | Research Growth Index | 4.66 (4.65) | | Search Engine Demand Index | 56.40 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |